AUTHOR=Daniels Martin A. , Fischer-Posovszky Pamela , Boschmann Michael , Jumpertz-von Schwartzenberg Reiner , Müller Timo D. , Sandforth Leontine , Frank-Podlech Sabine , Hülskämper Sonja , Peter Andreas , Wabitsch Martin , Jordan Jens , Birkenfeld Andreas L. 

TITLE=Atrial natriuretic peptide and leptin interactions in healthy men

JOURNAL=Frontiers in Endocrinology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1195677

DOI=10.3389/fendo.2023.1195677

ISSN=1664-2392

ABSTRACT=<sec><title>Introduction</title><p>Atrial natriuretic peptide (ANP), a hormone secreted from the heart, controls cardiovascular and renal functions including arterial blood pressure and natriuresis. ANP also exerts metabolic effects in adipose tissue, liver and skeletal muscle, and interacts with the secretion of adipokines. We tested the hypothesis that ANP lowers concentrations of the anorexigenic adipokine leptin in healthy humans <italic>in vivo</italic>.</p></sec><sec><title>Methods</title><p>Human ANP or matching placebo was infused intravenously (iv) into healthy men in a controlled clinical trial.</p></sec><sec><title>Results</title><p>Within 135 minutes of iv ANP infusion, we observed an acute decrease in plasma leptin levels compared to controls. Free fatty acids markedly increased with ANP infusion <italic>in vivo</italic>, indicating activated lipolysis. In human SGBS adipocytes, ANP suppressed leptin release.</p></sec><sec><title>Discussion</title><p>The study shows that the cardiac hormone ANP reduces the levels of the anorexigenic adipokine leptin in healthy humans, providing further support for ANP as a cardiomyokine in a heart - adipose tissue axis. (registered in the German Clinical Trials Register and the WHO International Clinical Trials Registry Platform was granted under <bold>DRKS00024559</bold>)</p></sec>